Sun Xiao-Dong, Zhang Zai-Xing, Wang Jian, Deng Yan, Yang Yuan-Chuan, Lasi Ja-Hkawn, Sun Xiao-Ying, Wang Heng
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2011 Oct;29(5):372-5.
To assess the efficacy and safety of compound dihydroartemisinin/piperaquine (DHAPIP) for treating uncomplicated falciparum malaria in Laiza city of Myanmar at the China-Myanmar border area.
A clinical trial was conducted in Laiza City and its four suburban natural villages bordering with China from September to December in 2008. Patients (aged 2-60 years) infected by Plasmodium falciparum without clinical complications (> or = 250 asexual parasite x microl(-1) of whole blood) were recruited for the assessment. The cases were given a 2-day course with DHAPIP tablets each containing 40 mg of dihydroartemisinin and 320 mg of piperaquine phosphate, and the total dosage varied with the body weight. For example, a patient with 50 kg body weight was given 8 tablets divided into 4 times at an interval of 8-10 h. The cases were then followed-up at DO, D1, D2, D3, D7, D14, D21 and D28 for observing their symptoms, the density of parasite, body temperature and side reaction. The therapeutic efficacy was assessed by using WHO classification of therapeutic response to the treatment of antimalarial drugs, including the time of fever subsidence, the clearance time of asexual parasites and the clearance rate of gametocytes.
Among the 74 cases enrolled, 64 completed 28-day follow-up. The therapeutic efficacy reached 100% with adequate clinical and parasitological responses. The mean fever subsidence time was (22.5 +/- 8.2) h. The median of clearance time of asexual parasites in blood was 30.0 h [(17.1-168.2) h]. The rate of eliminating asexual parasites and fever subsidence in D3 and D7 was (93.8% and 100%) and (100% and 100%), respectively. The clearance rate of gametocytes in day-28 was 75.0%. It showed 9.9% of side reaction with 7 cases suffering from mild adverse responses among 71 of full-course medication.
DHAPIP is efficacious and safe for the treatment of uncomplicated falciparum malaria in Laiza city of Myanmar in the border area.
评估复方双氢青蒿素/磷酸哌喹(DHAPIP)治疗中缅边境地区缅甸腊戍市非复杂性恶性疟的疗效和安全性。
2008年9月至12月在腊戍市及其与中国接壤的4个城郊自然村开展一项临床试验。招募年龄在260岁、感染恶性疟原虫且无临床并发症(全血中无性疟原虫≥250个/μl)的患者进行评估。给予患者服用含40 mg双氢青蒿素和320 mg磷酸哌喹的DHAPIP片,疗程为2天,总剂量根据体重而定。例如,体重50 kg的患者服用8片,分4次服用,间隔810小时。然后在第0、1、2、3、7、14、21和28天对患者进行随访,观察其症状、疟原虫密度、体温和不良反应。采用世界卫生组织对抗疟药物治疗反应的分类评估治疗效果,包括退热时间、无性疟原虫清除时间和配子体清除率。
纳入的74例患者中,64例完成了28天随访。临床和寄生虫学反应良好,治疗有效率达100%。平均退热时间为(22.5±8.2)小时。血液中无性疟原虫清除时间的中位数为30.0小时[(17.1~168.2)小时]。第3天和第7天无性疟原虫清除率和退热率分别为(93.8%和100%)以及(100%和100%)。第28天配子体清除率为75.0%。全程用药的71例患者中有7例出现轻度不良反应,不良反应发生率为9.9%。
DHAPIP治疗中缅边境地区缅甸腊戍市非复杂性恶性疟疗效确切且安全。